LGC Clinical Diagnostics Inc.
Milford, MA Part of Seracare Life Sciences Holdings, LLC
- UEI
- P94GFH7KA3F4
- CAGE
- 3Y6A3
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
DRMLCUMGH7W7
-
Parent
DRMLCUMGH7W7
- SAM.gov registration date
- Physical address
- 37 Birch St, Milford, MA 01757, USA
- Website
- lgcgroup.com
- Founded
- 1996
- Employees
- 1K-5K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $58,210 |
| FY2025 | $60,496 |
| FY2024 | $46,672 |
| FY2023 | $170,428 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $58,210 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Rapid test for recent HIV infection and incidence panels for assay evaluation | National Institutes of Health | $599,264 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Meridian Bioscience Inc. | Cincinnati, OH | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Bio Rad Laboratories Inc. | Hercules, CA | 334516 Analytical Laboratory Instrument Manufacturing |
| Biofire Diagnostics LLC | Salt Lake City, UT | 334516 Analytical Laboratory Instrument Manufacturing |
| Gold Standard Diagnostics, LLC | Davis, CA | 334516 Analytical Laboratory Instrument Manufacturing |
| Cepheid | Sunnyvale, CA | 334516 Analytical Laboratory Instrument Manufacturing |
About the company
LGC Clinical Diagnostics Inc., Clinical Diagnostics Division, a foreign-owned, for-profit subsidiary of Seracare Life Sciences Holdings LLC, supplies clinical diagnostic products, reference materials, calibration verification kits, and laboratory reagents to federal health agencies as a prime contractor exclusively — the company does not subcontract. Headquartered in Milford, Massachusetts, LGC Clinical Diagnostics competes on full-and-open purchase orders with no set-aside designations across 183 recent prime awards.
LGC Clinical Diagnostics' capability portfolio centers on in-vitro diagnostic substances, control products, reference materials, and validation testing services. The company manufactures linearity kits for clinical analyzers (Roche COBAS systems, Ortho 3600 instruments), external run controls for serological and viral marker validation, calibration verification test sets for cardiac diagnostic equipment, laboratory panels, and diagnostic reagents — all supporting FDA and CLIA compliance in federal clinical laboratory environments. Representative work includes a $14.4 thousand Indian Health Service purchase order for QI linearity reagents for the Mescalero Laboratory Department (October 2026), a $43.8 thousand NIH Clinical Center order for diagnostic products (April 2026), a $74 thousand Veterans Health Administration order for eight categories of linearity kits to validate Roche COBAS analyzers at the Texas Valley Coastal Bend Health Care System in Harlingen, Texas (January 2026), a $47 thousand Defense Health Agency order for calibration verification and linearity test kits for cardiac equipment and Maine standard reagents performed in Italy (September 2024), and a $78 thousand CDC purchase order for laboratory panels (September 2023).
Customer concentration by potential value is extreme and reveals a structural dependency: the National Institutes of Health National Cancer Institute anchors $155.6 million across just two awards — 92% of the combined portfolio's $169.6 million potential value. The broader Department of Health and Human Services ecosystem accounts for 98% of combined potential value. By award count, the top five customer agencies span NIH Clinical Center (13 awards, $215 thousand), CDC Office of Acquisition Services (12 awards, $1.7 million), CDC Pittsburgh (10 awards, $282 thousand), VA Veterans Integrated Service Network 6 (9 awards, $326 thousand), and VA Veterans Integrated Service Network 17 (8 awards, $175 thousand). LGC Clinical Diagnostics places task orders under two indefinite delivery vehicles: VA24612D0014 (5 task orders, $158 thousand combined potential value) and W81K0407D0023 (3 task orders, $189 thousand combined potential value).
Activity has contracted sharply: five awards in 2022, seven in 2023, then two in 2024 and two in 2025, with three awarded to date in 2026. Only $26.7 million of the $169.6 million combined potential value has been obligated (16% realization rate), indicating substantial unexercised ceiling exposure. Just two awards face completion within the next twenty-four months (combined potential value $88 thousand), resulting in minimal near-term recompete pressure. The primary NAICS coding for the portfolio is in-vitro diagnostic substance manufacturing (60 awards), with supporting categories including testing laboratories and services (10 awards) and analytical laboratory instrument manufacturing (9 awards).
Quick answers
Is LGC Clinical Diagnostics Inc. registered in SAM.gov?
Yes. LGC Clinical Diagnostics Inc.'s SAM.gov registration is active through September 21, 2027.
How much has LGC Clinical Diagnostics Inc. received in federal contracts?
Federal contracts obligated $60,496 to LGC Clinical Diagnostics Inc. in fiscal year 2025 and $335,806 in fiscal years 2023 through 2027.
How does LGC Clinical Diagnostics Inc. rank among federal contractors?
LGC Clinical Diagnostics Inc. ranked #22 in PSC H966, #31 in PSC H166 and #77 in NAICS 325414 in FY2025.
What is LGC Clinical Diagnostics Inc.'s most recent federal award?
LGC Clinical Diagnostics Inc.'s most recent federal contract award is QI linearity reagents for MSU laboratory department (75H70726P00141), from Indian Health Service, on October 1, 2026.
On GovTribe
See LGC Clinical Diagnostics Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors